Urology. 2006 Sep;68(3):578-82.
Inactivation of myopodin expression associated with prostate cancer relapse.
Yu YP, Tseng GC, Luo JH.

Acta Oncol. 2008;47(8):1539-45.
Aberrant expression of cyclin E in low-risk node negative breast cancer.
Ahlin C, Gruhne B, Holmqvist M, Zetterberg A, Fjällskog ML.

Breast Cancer Res Treat. 2010 Jul;122(2):315-24.
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.

Pancreas. 2009 Apr;38(3):259-66.
Neurogenin 3 and neurogenic differentiation 1 are retained in the cytoplasm of multiple endocrine neoplasia type 1 islet and pancreatic endocrine tumor cells.
Lejonklou MH, Edfeldt K, Johansson TA, Stålberg P, Skogseid B.

Horm Metab Res. 2008 May;40(5):354-9.
Lack of nuclear expression of hairy and enhancer of split-1 (HES1) in pancreatic endocrine tumors.
Johansson T, Lejonklou MH, Ekeblad S, Stålberg P, Skogseid B.

Leuk Lymphoma. 2010 Jul;51(7):1269-77.
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial.
Goy A, Bernstein SH, McDonald A, Pickard MD, Shi H, Fleming MD, Bryant B, Trepicchio W, Fisher RI, Boral AL, Mulligan G.

Clin Cancer Res. 2006 Jul 1;12(13):4080-9.
PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.
Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, Storici P, Zugnoni P, Pesenti E, Croci V, Ceruti R, Giorgini ML, Cappella P, Ballinari D, Sola F, Varasi M, Bravo R, Moll J.